Fall 2026
Technical Artist Intern
3D Artist
Updated on 9/4/2026
Zeiss
1,001-5,000 employees
Supplies lithography optics for semiconductor manufacturing
No salary listed
Oberkochen, Germany
Hybrid
Mix of remote and on-site work.
Bachelor's
 Art, Graphics & Animation (1) |
|---|
Get referred to Zeiss
See people who can refer or advise you
- Be enrolled in a degree program in 3D Design, Digital Media, Media Informatics, Computer Graphics, Visual Computing, Game Technology, Computer Science, Animation, Industrial Design, Virtual Reality, Human-Computer Interaction, Digital Content Creation, or a related field.
- Have solid experience with Blender acquired through coursework, personal projects, freelance work, studio work, open-source contributions, or hobby projects.
- Understand topology, mesh optimization, UV workflows, material creation, texturing, asset pipelines, and scene organization.
- Have experience with physically based rendering workflows and modern rendering concepts, as well as creating high-quality 3D assets.
- Have good visual design skills and strong attention to detail.
- Be able to work independently while collaborating effectively with interdisciplinary teams.
- Have good communication skills in English.
- Research, design, implement, and optimize high-quality 3D assets for visualization, simulation, and digital twin applications.
- Create, refine, and maintain high-quality 3D assets for digital twin applications.
- Optimize existing models and develop new assets in Blender for real-time visualization and simulation.
- Build clean and efficient geometry, topology, UV layouts, and material setups.
- Create physically based rendering materials and textures for realistic visual appearance.
- Support the integration of assets into the visualization and simulation pipeline.
- Collaborate with developers, graphics engineers, and researchers to ensure technical compatibility and visual quality.
- Work with robotics and mechatronic models, including URDF-based descriptions.
- Contribute to visual experiments and technology demonstrators used for evaluating future products.
- Rigging and animation experience.
- Python scripting in Blender or programming in Python/C++.
- Experience with Unreal Engine or Unity.
- Familiarity with robotics visualization, CAD conversion, product visualization, or simulation environments.
- Knowledge of common 3D asset formats such as glTF, USD, FBX, or URDF.
- A portfolio showcasing relevant work, such as ArtStation, Behance, GitHub, a personal website, demo videos, or project showcases.
Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS SMT opened its Korea Innovation Center in July 2026, deepening customer access.
- July 24, 2026 capacity expansion adds 25,000 square meters in Oberkochen.
- ASML expects 2027 EUV output growth, with Zeiss optics capacity already expanding.
What critics are saying
- ASML bought €4.41 billion from Zeiss in 2025; customer concentration is extreme.
- A prolonged Oberkochen outage would halt ASML production within months.
- Monument Peak sued Zeiss on February 6, 2026 over Kodak patents.
What makes Zeiss unique
- ZEISS SMT remains ASML's sole EUV optics supplier in 2026.
- Oberkochen and Wetzlar are the only places building ASML optical columns.
- High-NA EUV optics from ZEISS anchor sub-2nm lithography for Intel and TSMC.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.